BLUEPRINT FOR PROGRESS

Experts and veterans examine and explore strategies for India Pharma Inc to implement the lessons learnt from the COVID-19 pandemic as we enter a new year and a new decade

- 

The industry has focused on innovating business models in ways that are more patient-centric

The approval and launch of the COVID-19 vaccines is a beacon of hope as we enter 2021. Economic activity across markets has started normalising and we will continue to see stable trends and recovery and expect this momentum to be accelerated, particularly with the rollout of the vaccine.

The generic pharma industry has been focused on ensuring access of medicines to patients during these tough times and has ensured a stable supply chain through the pandemic. The industry has also focused on exploring ways of innovating business models in ways that are more patient centric. Industry has leveraged technology to deliver information and medicines to patients and physicians in the backdrop of reduced in-person interactions.